title: rhDNase in cystic fibrosis.
abstract: Cystic fibrosis (CF) affects approximately 1 in 2500 live births in the UK Caucasian population. Morbidity and mortality closely reflect the degree of pulmonary involvement. rhDNase is a new form of therapy in CF care. Phase 1, 2 and 3 trials have shown it to be well-tolerated, with patients showing initial increases in respiratory function of around 13% from baseline. A years prescription costs $7500. This review discusses our views on how this expensive new therapy can best be used.
authors.affiliation: Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds.
authors.forename: S P
authors.initials: SP
authors.lastname: Conway
authors.forename: J M
authors.initials: JM
authors.lastname: Littlewood
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000627:therapeutic use*; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D018579:Patient Selection; D012119:Respiration / Q000187:drug effects
chemical_list: D003850:Deoxyribonuclease I